The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | The evolving treatment paradigm for BRAF V600E-mutant mCRC
Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, describes the current and future treatment options for patients with microsatellite instability (MSI)-high BRAF V600E-mutant metastatic colorectal cancer (mCRC). Trials are currently underway to assess cetuximab with EFGR antibodies and the Phase III BREAKWATER trial (NCT04607421) assess encorafenib, a BRAF inhibitor, with cetuximab. Prof. Stintzing additionally highlights research elucidating mechanisms of resistance to current treatments. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
